Chronic lymphocytic leukemia;Chronische lymphatische Leukämie

Deutsche Medizinische Wochenschrift

Volumn 138, Issue 42, 2013, Pages 2153-2166

  Maurer, C ^a   Hallek, M ^a  

^a UNIVERSITY HOSPITAL OF COLOGNE   (Germany)

Author keywords

chronic lymphocytic leukemia; diagnosis; therapy

Indexed keywords

CHRONIC LYMPHATIC LEUKEMIA; REVIEW;

ADULT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CROSS-SECTIONAL STUDIES; EARLY MEDICAL INTERVENTION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; NEOPLASM STAGING; WATCHFUL WAITING;

EID: 84885394550     PISSN: 00120472     EISSN: 14394413     Source Type: Journal    
DOI: 10.1055/s-0033-1349491     Document Type: Review

References (26)

1. Binet J. L., Auquier A., Dighiero G. et al. A new prognostic classification of chronic lymphocytic leukemia derived from a multivariate survival analysis. Cancer: 1981; 48 198 206 (Pubitemid 11064396)
2. Damle R. N., Wasil T., Fais F. et al. Ig V gene mutation status and CD38 expression as novel prognostic indicators in chronic lymphocytic leukemia. Blood: 1999; 94 1840 7 (Pubitemid 29430399)
3. Dighiero G., Binet J. L. Chronic lymphocytic leukemia. Hematol Cell Ther: 1996; 38 02 41 61
4. Döhner H., Stilgenbauer S., Benner A. et al. Genomic aberrations and survival in chronic lymphocytic leukemia. N Engl J Med: 2000; 343 1910 6 (Pubitemid 32064784)
5. Eichhorst B. F., Busch R., Stilgenbauer S. et al. First-line therapy with fludarabine compared with chlorambucil does not result in a major benefit for elderly patients with advanced chronic lymphocytic leukemia. Blood: 2009; 114 3382 3391
6. Extermann M., Overcash J., Lyman G. H. et al. Comorbidity and functional status are independent in older cancer patients. J. Clin. Oncol: 1998; 16 1582 7 (Pubitemid 28175784)
7. Ferrajoli A., Badoux X. C., O'Brien S. et al. Combination Therapy with Lenalidomide and Rituximab in Patients with Relapsed Chronic Lymphocytic Leukemia (CLL). ASH Annual Meeting Abstracts: 2009; 114 206
8. Ferrajoli A., Lee B-N, Schlette E. J. et al. Lenalidomide induces complete and partial remissions in patients with relapsed and refractory chronic lymphocytic leukemia. Blood: 2008; 111 5291 7
9. Fischer K., Cramer P., Busch R. et al. Bendamustine in combination with rituximab for previously untreated patients with chronic lymphocytic leukemia: a multicenter phase II trial of the German Chronic Lymphocytic Leukemia Study Group. J Clin Oncol: 2012; 30 3209 16
10. Hallek M., Cheson B. D., Catovsky D. et al. Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines. Blood: 2008; 111 5446 56
11. Hallek M., Emmerich B., Bergmann M. et al. Chronische lymphatische Leukämie. Bremen Uni-Med: 2009
12. Hallek M., Fischer K., Fingerle-Rowson G. et al. Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial. Lancet: 2010; 376 1164 74
13. Hallek M., Pflug N. State of the art treatment of chronic lymphocytic leukaemia. Blood reviews: 2011; 25 1 9
14. Hallek M., Wanders L., Ostwald M. et al. Serum beta(2)-microglobulin and serum thymidine kinase are independent predictors of progression-free survival in chronic lymphocytic leukemia and immunocytoma. Leuk. Lymphoma: 1996; 22 439 47 (Pubitemid 26341010)
15. Hamblin T. J., Davis Z., Gardiner A. et al. Unmutated Ig V(H) genes are associated with a more aggressive form of chronic lymphocytic leukemia. Blood: 1999; 94 1848 54 (Pubitemid 29430400)
16. Hansen M. M. Chronic lymphocytic leukaemia. Clinical studies based on 189 cases followed for a long time. Scand J Haematol Suppl: 1973; 18 3 286
17. Hillmen P., Skotnicki A. B., Robak T. et al. Alemtuzumab compared with chlorambucil as first-line therapy for chronic lymphocytic leukemia. J Clin Oncol: 2007; 25 5616 23
18. Ibrahim S., Keating M., Do K. A. et al. CD38 expression as an important prognostic factor in B-cell chronic lymphocytic leukemia. Blood: 2001; 98 181 6
19. Knauf W. U., Langenmayer I., Ehlers B. et al. Serum levels of soluble CD23, but not soluble CD25, predict disease progression in early stage B-cell chronic lymphocytic leukemia. Leuk Lymphoma: 1997; 27 523 32 (Pubitemid 28029915)
20. Lin T. S., Ruppert A. S., Johnson A. J. et al. Phase II study of flavopiridol in relapsed chronic lymphocytic leukemia demonstrating high response rates in genetically high-risk disease. J Clin Oncol: 2009; 27 6012 8
21. Montserrat E., Bosch F., Rozman C. B-cell chronic lymphocytic leukemia: recent progress in biology, diagnosis, and therapy. Ann. Oncol: 1997; 8 01 93 101
22. Orchard J. A., Ibbotson R. E., Davis Z. et al. ZAP-70 expression and prognosis in chronic lymphocytic leukaemia. Lancet: 2004; 363 105 11 (Pubitemid 38068326)
23. Pettitt A. R., Matutes E., Oscier D. Alemtuzumab in combination with high-dose methylprednisolone is a logical, feasible and highly active therapeutic regimen in chronic lymphocytic leukaemia patients with p53 defects. Leukemia: 2006; 20 1441 5 (Pubitemid 44084061)
24. Rai K. R., Sawitsky A., Cronkite E. P. et al. Clinical staging of chronic lymphocytic leukemia. Blood: 1975; 46 219 34
25. Wiestner A. Emerging role of kinase-targeted strategies in chronic lymphocytic leukemia. Blood: 2012; 120 4684 4691
26. Zenz T., Eichhorst B., Busch R. et al. TP53 mutation and survival in chronic lymphocytic leukemia. J Clin Oncol: 2010; 28 4473 9